GUANGJI PHARMA.(SZ:000952)2022-12-05 05:38Group 1: Company Performance - The price of Vitamin B2 has gradually increased since 2015, stabilizing at a relatively high level in 2016, with a significant price rise compared to 2015 [3] - In 2016, the main product sales prices saw a substantial increase compared to 2015, maintaining a good price range [3] - The company implemented a strategy of controlled quantity price increases in 2016, which contributed to improved production costs due to low prices of raw materials like corn starch and coal [3] Group 2: Sales and Revenue - The sales revenue from formulations has significantly increased, attributed to a rise in retail prices from around 2 yuan to over 3 yuan per bottle [4] - The company plans to expand the production of pharmaceutical-grade B2 tablets, addressing capacity bottlenecks as a key challenge [4] Group 3: Future Outlook and Challenges - The company is facing challenges such as product singularity and weak profitability, heavily influenced by market conditions [4] - The leadership change in the provincial investment group is expected to provide more stable and favorable support for the company in 2017 [5] - The company aims to explore external development paths despite past setbacks in expansion plans [4]